Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 1, 2016, Pages E12-E22

  Bavishi, Chirag ^a   Koulova, Anna ^a   Bangalore, Sripal ^b   Sawant, Ashwin ^a   Chatterjee, Saurav ^a   Ather, Sameer ^c   Valencia, Jose ^d   Sarafoff, Nikolaus ^e   Rubboli, Andrea ^f   Airaksinen, Juhani K ^g   Lip, Gregory Y H ^h,i   Tamis Holland, Jacqueline E ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALICANTE   (Spain)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f MAGGIORE HOSPITAL   (Italy)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ AALBORG UNIVERSITY   (Denmark)

Author keywords

ACS; ACS MSTEMI; dual antiplatelet therapy DAPT; META; meta analysis; triple therapy TT

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CHRONIC ANTICOAGULATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84978818146     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26234     Document Type: Article

References (46)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502.
2. Steinhubl SR, Berger PB, Mann JT, 3rd Fry ET, DeLago A, Observation CICftRoED, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411–2420.
3. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New Engl J Med 2005;352:1179–1189.
4. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618–1623.
5. Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. Am Heart J 2008;155:361–368.
6. Rubboli A, Colletta M, Valencia J, Capecchi A, Franco N, et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009;22:390–397.
7. Andrade JG, Deyell MW, Khoo C, Lee M, Humphries K, et al. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: A systematic review and meta-analysis. Can J Cardiol 2013;29:204–212.
8. Authors/Task Force, Windecker S, Kolh P, Alfonso F, Collet JP, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
9. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155–3179.
10. Fosbol EL, Wang TY, Li S, Piccini JP, Lopes RD, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J 2012;163:720–728.
11. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981–989.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
14. Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature. JAMA 2014;312(12):171–179.
15. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97–111.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
18. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463.
19. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010;74:701–708.
20. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009;104:338–342.
21. Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. EuroIntervention 2013;8:1061–1071.
22. Sambola A, Ferreira-Gonzalez I, Angel J, Alfonso F, Maristany J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 2009;95:1483–1488.
23. Sarafoff N, Ndrepepa G, Mehilli J, Dorrler K, Schulz S, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008;264:472–480.
24. Valencia J, Mainar V, Bordes P, Pineda J, Gomez S, et al. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J Interv Cardiol 2008;21:218–224.
25. Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: An analysis of the AFCAS registry. Clin Cardiol 2014;37:357–364.
26. Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, et al. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: Data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol 2014;26:563–569.
27. Dabrowska M, Ochala A, Cybulski W, Tendera M. Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution? Postepy Kardiol Interwencyjnej 2013; 9:234–240.
28. Ho KW, Ivanov J, Freixa X, Overgaard CB, Osten MD, et al. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation. Can J Cardiol 2013;29:213–218.
29. Maegdefessel L, Schlitt A, Faerber J, Bond SP, Messow CM, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) 2008;103:628–632.
30. Manzano-Fernandez S, Pastor FJ, Marin F, Cambronero F, Caro C, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008;134:559–567.
31. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818–825.
32. Goto K, Nakai K, Shizuta S, Morimoto T, Shiomi H, et al. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 2014;114:70–78.
33. Suh SY, Kang WC, Oh PC, Choi H, Moon CI, et al. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels 2014;29:578–583.
34. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–e76.
35. American College of Emergency Physicians and Society for Cardiovascular Angiography Interventions, O'Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78–e140.
36. Task Force on the Management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–2619.
37. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060–2066.
38. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR–TRIPLE Trial. J Am Coll Cardiol 2015;65:1619–1629.
39. Kwok CS, Rao SV, Myint PK, Keavney B, Nolan J, et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: A systematic review and meta-analysis. Open Heart 2014;1:e000021.
40. Investigators AWGotA, Connolly S, Pogue J, Hart R, Pfeffer M, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367:1903–1912.
41. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008;39:1482–1486.
42. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107–1115.
43. Le May MR, Acharya S, Wells GA, Burwash I, Chong AY, et al. Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2015;8(1 Pt B):155–162.
44. Sambola A, Montoro JB, Del Blanco BG, Llavero N, Barrabes JA, et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Am Heart J 2013;166:669–675.
45. Boehringer Ingelheim. Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI). 2013 Jun 13 [update 2015 Sept 1; cited 2015 Sept 7] Available from: https://clinicaltrials.gov/ct2/show/NCT02164864.
46. Scientific Affairs, LLC. AJanssen Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI). 2013 Mar 19 [update 2015 Aug 16; cited 2015 Sept 7] Available from: https://clinicaltrials.gov/ct2/show/NCT01830543?term=pioneer+af+pci&rank=1.